Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lu, Fang
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss	Recruiting	3	350	RoW	601 1.25mg, 601, ranibizumab 0.5mg, Lucentis	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Branch Retinal Vein Occlusion	12/25	12/25
NCT05420220: Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer	Recruiting	2	54	RoW	KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Advanced Non-small Cell Lung Cancer	05/27	12/27